NeuroMetrix, Inc. (NURO): Price and Financial Metrics


NeuroMetrix, Inc. (NURO): $1.92

0.01 (+0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NURO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NURO POWR Grades

  • Value is the dimension where NURO ranks best; there it ranks ahead of 64.82% of US stocks.
  • NURO's strongest trending metric is Growth; it's been moving down over the last 116 days.
  • NURO ranks lowest in Growth; there it ranks in the 5th percentile.

NURO Stock Summary

  • NURO has a higher market value than only 4.63% of US stocks; more precisely, its current market capitalization is $14,661,157.
  • With a year-over-year growth in debt of -43.34%, NEUROMETRIX INC's debt growth rate surpasses just 6.54% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, NEUROMETRIX INC is reporting a growth rate of 194.71%; that's higher than 92.11% of US stocks.
  • If you're looking for stocks that are quantitatively similar to NEUROMETRIX INC, a group of peers worth examining would be CRNT, AIM, NAVB, HSTO, and SIGA.
  • Visit NURO's SEC page to see the company's official filings. To visit the company's web site, go to www.neurometrix.com.

NURO Valuation Summary

  • In comparison to the median Healthcare stock, NURO's price/earnings ratio is 113.57% lower, now standing at -3.
  • NURO's price/earnings ratio has moved up 3.7 over the prior 226 months.

Below are key valuation metrics over time for NURO.

Stock Date P/S P/B P/E EV/EBIT
NURO 2023-01-30 1.7 0.7 -3.0 -2.7
NURO 2023-01-27 1.8 0.7 -3.1 -2.8
NURO 2023-01-26 1.7 0.7 -3.0 -2.7
NURO 2023-01-25 1.9 0.7 -3.3 -3.0
NURO 2023-01-24 1.8 0.7 -3.1 -2.8
NURO 2023-01-23 1.8 0.7 -3.1 -2.8

NURO Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at 50.93%.
  • The 4 year net cashflow from operations growth rate now stands at 67.57%.
  • The 3 year price growth rate now stands at -59.45%.
NURO's revenue has moved down $9,061,955 over the prior 49 months.

The table below shows NURO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.228858 -4.318874 -4.72774
2022-06-30 8.325214 -3.083638 -3.808575
2022-03-31 8.400412 -2.780285 -3.180236
2021-12-31 8.253493 -2.073694 -2.281457
2021-09-30 8.243062 -1.280035 -1.604223
2021-06-30 8.214931 -0.803839 -1.174247

NURO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NURO has a Quality Grade of D, ranking ahead of 21.62% of graded US stocks.
  • NURO's asset turnover comes in at 0.625 -- ranking 66th of 186 Medical Equipment stocks.
  • BLFS, NVNO, and ZYXI are the stocks whose asset turnover ratios are most correlated with NURO.

The table below shows NURO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.625 0.729 -0.970
2021-06-30 0.944 0.739 -0.690
2021-03-31 0.902 0.717 -0.828
2020-12-31 0.948 0.712 -1.087
2020-09-30 0.969 0.684 -1.415
2020-06-30 0.970 0.635 -1.936

NURO Stock Price Chart Interactive Chart >

Price chart for NURO

NURO Price/Volume Stats

Current price $1.92 52-week high $5.89
Prev. close $1.91 52-week low $1.33
Day low $1.90 Volume 40,169
Day high $1.98 Avg. volume 87,545
50-day MA $1.64 Dividend yield N/A
200-day MA $2.78 Market Cap 14.89M

NeuroMetrix, Inc. (NURO) Company Bio


NeuroMetrix Inc. is a medical device company that designs, develops and sells proprietary products used to diagnose neuropathies. The Company's neuropathy diagnostic system provides primary care and specialist physicians objective information that aids in the diagnosis of neuropathies at the point of service.


NURO Latest News Stream


Event/Time News Detail
Loading, please wait...

NURO Latest Social Stream


Loading social stream, please wait...

View Full NURO Social Stream

Latest NURO News From Around the Web

Below are the latest news stories about NEUROMETRIX INC that investors may wish to consider to help them evaluate NURO as an investment opportunity.

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania. Quell Fibromyalgia is a wearable neuromodulation technology that is the first and only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company’s booth #1745 for a demonstration an

Yahoo | November 8, 2022

NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia

WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell ® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the symptoms of fibromyalgia.

GlobeNewswire | November 3, 2022

NeuroMetrix Inc. (NASDAQ:NURO) Rises 3.82%, But An Additional Surge May Follow.

In recent trading session, NeuroMetrix Inc. (NASDAQ:NURO) saw 9.21 million shares changing hands at last check today with its beta currently measuring 2.37. Company’s recent per share price level of $1.63 trading at $0.06 or 3.82% at last check today assigns it a market valuation of $11.93M. That most recent trading price of NURO’s stock … NeuroMetrix Inc. (NASDAQ:NURO) Rises 3.82%, But An Additional Surge May Follow. Read More »

Marketing Sentinel | November 3, 2022

Earnings Scheduled For October 20, 2022

Companies Reporting Before The Bell • ABB (NYSE: ABB ) is estimated to report quarterly earnings at $0.38 per share on revenue of $7.35 billion. • Nokia (NYSE: NOK ) is expected to report quarterly earnings at $0.10 per share on revenue of $6.32 billion. • Telefonaktiebolaget L M (NASDAQ: ERIC ) is estimated to report quarterly earnings at $0.16 per share on revenue of $6.18 billion. • Quest Diagnostics (NYSE: DGX ) is projected to report quarterly earnings at $2.17 per share on revenue of $2.33 billion. • Banc of California (NYSE: BANC ) is projected to report quarterly earnings at $0.47 per share on revenue of $84.68 million. • Nucor (NYSE: NUE ) is likely to report quarterly earnings at $6.69 per share on revenue of $10.03 billion. • CLPS (NASDAQ: CLPS ) is estimated to report earnin...

Benzinga | October 20, 2022

NeuroMetrix Reports Q3 2022 Financial Results

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

GlobeNewswire | October 20, 2022

Read More 'NURO' Stories Here

NURO Price Returns

1-mo 31.96%
3-mo 20.75%
6-mo -47.25%
1-year -56.95%
3-year -34.47%
5-year -87.28%
YTD 28.86%
2022 -70.32%
2021 58.86%
2020 -26.51%
2019 -43.42%
2018 -56.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.65 seconds.